Chemotherapy/immunotherapy combo shows promise for first-line treatment of mesothelioma
Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of…
Browsing: durvalumab
Phase II trial shows activity of durvalumab in recurrent/metastatic head and neck cancer
Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is…
ESMO and Immunotherapy by Ian Olver
ESMO 2017 Conference Review by Professor Ian Olver AM, for oncologynews.com.au. Almost 24,000 delegates gathered in Madrid…